Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | QoL of patients with R/R Hodgkin lymphoma treated with pembrolizumab vs brentuximab vedotin

John Kuruvilla • 11 Jun 2022
EHA 2022
Hodgkin Lymphoma Lymphoma Brentuximab vedotin Pembrolizumab

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, comments on the findings of a study comparing the quality of life (QoL) of patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (HL) treated with pembrolizumab vs brentuximab vedotin. The study demonstrated that pembrolizumab was more effective and better tolerated than brentuximab vedotin. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Karyopharma, DSB; Honoraria from Karyopharma, Merck; Research funding from Merck

More from John Kuruvilla

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:06
Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL
John Kuruvilla • 12 Dec 2022
1:18
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
John Kuruvilla • 12 Dec 2022
0:49
Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla • 12 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals